Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

Author, yearIntervention (dose, schedule)Comparison (description)Patients (N)Age (years)Male (%)Cytogenetic risk group, N (%)ECOG scoreBone marrow blasts, median (range)Follow-up (months)
Azacitidine
 Fenaux et al. [15]Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q28 days for at least 6 cyclesCCR (BSC, LDAC 20 mg/m2/day for 14 days Q28 days for at least 6 cycles, IC)Intervention: 55
Comparison: 58
Intervention: 73 (64–89)
Comparison: 73 (64–91)
Intervention: 62.1
Comparison: 56.6
Intermediate: 81 (71.7%)
Normal: 52 (46.0%)
Poor risk: 27 (23.9%)
Missing: 5 (4.4%)
0–1: 107 (94.7%)
2: 4 (3.5%)
Missing: 2 (1.8%)
Intervention: 23.0 (20.0–34.0)
Comparison: 23.1 (13.0–68.9)
40
 Dombret et al. [16]Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q28 days for at least 6 cyclesCCR (BSC, LDAC 20 mg/m2/day for 14 days Q28 days for at least 6 cycles, IC)Intervention: 241
Comparison: 247
Intervention: 75 (64–91)
Comparison: 75 (65–89)
Intervention: 57.7
Comparison: 60.3
Intermediate: 306 (63.1%)
Normal: –
Poor risk: 174 (35.8%)
Missing: –
0-1: 375(76.8%)
2: 113(23.2%)
missing:–
Intervention: 70.0 (2.0–100.0)
Comparison: 72.0 (2.0–100.0)
> 50%: 366 (75.0%)
40
Decitabine
 Kantarjian et al. [17]Decitabine: intravenously 20 mg/m2 QD for 5 days, every 4 weeksTC (supportive care,or cytarabine 20 mg/m2 QD for 10 days, every 4 weeks)Intervention: 242
Comparison: 243
Intervention: 73 (64–89)
Comparison: 73 (64–91)
Intervention: 62.1
Comparison: 56.6
Intermediate: 306 (63.1%)
Normal: –
Poor risk: 174 (35.8%)
Missing: –
0–1: 367 (75.7%)
2: 118 (24.3%)
Missing: –
20–30%: 123 (25.2%)
> 30–50%: 141 (29.3%)
> 50%: 206 (42.7%)
36
  1. CCR conventional care regimens, BSC best supportive care, LDAC low-dose ara-c, IC induction chemotherapy, TC treatment choice, N total number of patients, ECOG Eastern Cooperative Oncology Group performance status